In the News

/In the News

Opioids: Destroying Lives and the Economy… Medical Innovation Needs to Step Up with Effective Alternative Solutions

Drug overdoses are now the leading cause of death among Americans under 50. The major contributor to this immense and growing public health crisis? Opioid addiction. As the opioid epidemic continues to destroy lives, it is also taking a toll on the U.S. economy.

2018-05-03T21:04:02+00:00October 19th, 2017|In the News|

Biotech Company Offers Neurotoxin Alternative to Opioid Pain Management

Surgeons are well aware that opioid dependency is a huge problem in the United States; it results in 80 to 90 overdose-related deaths every day, 40% of which are associated with prescrip- tion medications. But a product created by Bonti, a small biotech company in Newport Beach, Calif., could have the potential to reduce the use of opioids by providing [...]

2018-05-03T21:04:21+00:00October 1st, 2017|In the News|

A Drug Maker Wants to Use Botox Technology to Cure America’s Opioid Addiction

The growing opioid crises has sent health care experts scrambling for ways to address pain that doesn’t lead to addiction. In the labs of the biotech firm Bonti, scientists are working to see if the answer might be Botox-like technology.

2018-05-03T21:04:41+00:00September 25th, 2017|In the News|

The Solution to Combating the Nation’s Opioid Crisis

Fauad Hasan, President & CEO at Bonti, a privately-held, clinical-stage biotechnology company, discusses its LANTERN clinical program aimed at relieving musculoskeletal pain and reducing the use of opioids using its neurotoxin platform.

2018-05-03T21:04:49+00:00September 25th, 2017|In the News|

A drug maker wants to use Botox technology to cure America’s opioid addiction

The growing opioid crises has sent health care experts scrambling for ways to address pain that doesn’t lead to addiction. In the labs of the biotech firm Bonti, scientists are working to see if the answer might be Botox-like technology.

2018-05-03T21:04:53+00:00September 22nd, 2017|In the News|

Bonti Releases Phase 2A Clinical Study Data For Its Botulinum Toxin Product

Bonti, a clinical-stage biotechnology company, has announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours) and short duration of effect (about 4 weeks).

2018-05-03T21:05:00+00:00September 20th, 2017|In the News|